Areas of Focus
- GPCR and tumor immune regulation
- Development of innovative anti-tumor drugs targeting GPCR
Work Experience
- 2013-2017 Assistant Researcher, East China Normal University, School of Life Sciences
- 2018-2022 Associate Researcher, East China Normal University, School of Life Sciences
- 2022-present Researcher, East China Normal University, School of Life Sciences
Academic Background & Achievements
- 2004-2008 Bachelor's Degree: East China University of Science and Technology
- 2008-2013 PhD: East China University of Science and Technology
- Published over 50 research papers as first or corresponding author
- Applied for 20 domestic patents, granted 9
Publications
- PPIA dictates NRF2 stability to promote lung cancer progression, Weiqiang Lu et al., 2023
- Subtle Structural Changes across the Boundary between A2AR/A2BR Dual Antagonism and A2BR Antagonism: A Novel Class of 2-Aminopyrimidine-based Derivatives, Weiqiang Lu et al., 2024
- Discovery of a Highly Potent Oxysterol Receptor GPR183 Antagonist Bearing the Benzo[d]thiazole Structural Motif for the Treatment of Inflammatory Bowel Disease (IBD), Weiqiang Lu et al., 2024
Awards
- 2018: 22nd Chinese Pharmacological Society Young Pharmacologist Award
- 2019: 16th National Biochemistry and Molecular Pharmacology Conference Young Excellent Paper First Prize
- 2020: 'Internet+' Outstanding Instructor for College Students' Innovation and Entrepreneurship
- 2021: 5th National Matrix Biology Conference Young Report Second Prize
